Tetraphase Pharmaceuticals (TTPH) Now Covered by Analysts at B. Riley

Analysts at B. Riley assumed coverage on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) in a report issued on Monday, MarketBeat reports. The firm set a “buy” rating and a $11.00 price target on the biopharmaceutical company’s stock. B. Riley’s target price would indicate a potential upside of 101.47% from the stock’s current price.

A number of other research firms have also recently commented on TTPH. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, January 12th. HC Wainwright increased their target price on shares of Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, November 6th. ValuEngine cut shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Finally, BidaskClub cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $14.46.

Tetraphase Pharmaceuticals (NASDAQ TTPH) traded up $0.31 during mid-day trading on Monday, hitting $5.46. 442,899 shares of the stock were exchanged, compared to its average volume of 433,373. The company has a market capitalization of $265.71, a PE ratio of -1.91 and a beta of 2.29. Tetraphase Pharmaceuticals has a 52-week low of $4.91 and a 52-week high of $9.93.

In other news, Director L Patrick Gage acquired 3,880 shares of the stock in a transaction dated Wednesday, November 29th. The stock was bought at an average price of $6.45 per share, with a total value of $25,026.00. Following the completion of the purchase, the director now directly owns 38,880 shares of the company’s stock, valued at approximately $250,776. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jacques Dumas sold 7,167 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total value of $44,507.07. The disclosure for this sale can be found here. Corporate insiders own 5.50% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new position in shares of Tetraphase Pharmaceuticals in the third quarter valued at approximately $107,000. Brighton Jones LLC acquired a new position in shares of Tetraphase Pharmaceuticals in the third quarter valued at approximately $108,000. Voya Investment Management LLC increased its stake in shares of Tetraphase Pharmaceuticals by 17.8% in the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 3,104 shares during the period. Virtu KCG Holdings LLC acquired a new position in shares of Tetraphase Pharmaceuticals in the second quarter valued at approximately $147,000. Finally, Ameriprise Financial Inc. acquired a new position in shares of Tetraphase Pharmaceuticals in the second quarter valued at approximately $162,000. 58.28% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/12/tetraphase-pharmaceuticals-ttph-now-covered-by-analysts-at-b-riley.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply